Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary breast cancer~* Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy~* ≥19 years of age~* Able to provide verbal consent~Exclusion Criteria:~* Contraindication to Filgrastim

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neupogen for 5 days (Type: ACTIVE_COMPARATOR): Neupogen injection for 5 days
- Neupogen for 7 days (Type: ACTIVE_COMPARATOR): Neupogen injection for 7 days
- Neupogen for 10 days (Type: ACTIVE_COMPARATOR): Neupogen injection for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).